Literature DB >> 27570400

Narcolepsy in midbrain structural lesion.

Rosaria Renna1, Tatiana Koudriavtseva2, Antonio Renna3, Severino Renna3.   

Abstract

Entities:  

Year:  2016        PMID: 27570400      PMCID: PMC4980971          DOI: 10.4103/0972-2327.186844

Source DB:  PubMed          Journal:  Ann Indian Acad Neurol        ISSN: 0972-2327            Impact factor:   1.383


× No keyword cloud information.
A 59-year-old Caucasian man presented with a 2-year history of excessive daytime sleepiness associated with sudden and irresistible bouts of sleep occurring up to five times per day. Moreover, he reported occasional episodes of cataplexy that were triggered by strong emotional stimuli, especially anger and surprise. He had a depressed mood and was exhausted from his symptoms that caused him great difficulty in maintaining concentration while at work and had even led to a car crash. There was no relevant family history or any other previous sleep disorder. He was overweight [body mass index (BMI 29)] and used to take no medication. His past medical history was unremarkable; in particular, he denied any history of vivid dream-like images or hallucinations. He used to drink 4-5 cups of coffee throughout the day and one glass of wine most evenings and denied any use of illicit drugs. Neurological evaluation did not show any pathological finding. Epworth sleepiness scale score was 18 and all the laboratory tests, including thyroid function, were within normal values. The nocturnal polysomnogram did not show significant sleep-disordered breathing or periodic limb movement activity, while a multiple sleep latency test (MSLT) confirmed the suspected diagnosis of narcolepsy. Magnetic resonance imaging (MRI) of the brain revealed a midbrain T2-hyperintense lesion in the left paramedian area, next to the aqueduct of Sylvius [Figure 1]. Narcolepsy is a chronic lifelong sleep disorder, with a severe effect on the patients’ quality of life. It is a sporadic disorder with genetic susceptibility. Moreover, the strong association with human leukocyte antigen (HLA) DQ beta 1 (DQB1)*06:02 strongly suggests an autoimmune basis for the disease.[1] It is often misdiagnosed, or the diagnosis may be delayed, in part, because of the wide spectrum of clinical phenotypes. Age at onset is usually in the second or third decade, with a small peak in the fourth decade. Narcolepsy has been associated with deficiency of the hypothalamic neuropeptide hypocretin,[2] causing the classic tetrad of excessive daytime sleepiness, and sleep paralysis. Secondary etiologies due to hypothalamus or pons lesions have been described.[3] Our case, related to a midbrain ischemic lesion, extends the spectrum of structural lesions in narcolepsy.
Figure 1

Sagittal (A) and axial (2) T2-weighted MRI showing a hyperintense lesion localized in the left midbrain paramedian area (arrows), next to the aqueduct of Sylvius, corresponding to the median column of the midbrain reticular formation. The lesion, extending for 12 mm in the rostrocaudal plan, does not show contrast enhancement and is likely due to an ischemic damage

Sagittal (A) and axial (2) T2-weighted MRI showing a hyperintense lesion localized in the left midbrain paramedian area (arrows), next to the aqueduct of Sylvius, corresponding to the median column of the midbrain reticular formation. The lesion, extending for 12 mm in the rostrocaudal plan, does not show contrast enhancement and is likely due to an ischemic damage

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  3 in total

Review 1.  Effects of pontine lesions on REM sleep.

Authors:  Craig Carroll; Mark E Landau
Journal:  Curr Neurol Neurosci Rep       Date:  2014-07       Impact factor: 5.081

Review 2.  Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system.

Authors:  Seiji Nishino; Takashi Kanbayashi
Journal:  Sleep Med Rev       Date:  2005-08       Impact factor: 11.609

3.  HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients.

Authors:  E Mignot; R Hayduk; J Black; F C Grumet; C Guilleminault
Journal:  Sleep       Date:  1997-11       Impact factor: 5.849

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.